BACKGROUND: About 80% of women experience premenstrual symptoms (PMSx), and about 50% of women seek medical care for them, posing a large medical care burden. However, despite women's use of anti-inflammatory agents for relief from these symptoms, and the fact that anti-inflammatory agents provide relief from some PMSx, the relationship of inflammation to PMSx has not been well investigated. METHODS: We, therefore, undertook the present cross-sectional analyses using baseline data from the longitudinal Study of Women's Health Across the Nation (SWAN), a racially/ethnically diverse cohort of midlife women (n = 2939), to determine if a biomarker of inflammation, high-sensitivity C-reactive protein (hs-CRP), was associated with PMSx. We performed factor analyses with Varimax rotations to determine five groupings of eight symptoms to develop a parsimonious set of outcome variables. We conducted backward stepwise multiple logistic regression models for each grouping, eliminating non-significant (p > 0.05) covariates. RESULTS: Having an hs-CRP level >3 mg/L was significantly positively associated with premenstrual mood symptoms (adjusted odds ratio [aOR] = 1.27, 95% confidence interval [95% CI] 1.02-1.58), abdominal cramps/back pain (aOR = 1.40, 95% CI 1.09-1.80), appetite cravings/weight gain/bloating (aOR = 1.41, 95% CI 1.04-1.89), and breast pain (aOR = 1.26, 95% CI 1.02-1.55). Elevated hs-CRP level was not associated with premenstrual headaches or reporting three or more PMSx. CONCLUSIONS: The significant relationships of specific groups of PMSx with elevated hs-CRP levels have potential clinical implications for treatment and possibly for prevention by advising women about the factors associated with inflammation and the potential for treatment with anti-inflammatory agents.
BACKGROUND: About 80% of women experience premenstrual symptoms (PMSx), and about 50% of women seek medical care for them, posing a large medical care burden. However, despite women's use of anti-inflammatory agents for relief from these symptoms, and the fact that anti-inflammatory agents provide relief from some PMSx, the relationship of inflammation to PMSx has not been well investigated. METHODS: We, therefore, undertook the present cross-sectional analyses using baseline data from the longitudinal Study of Women's Health Across the Nation (SWAN), a racially/ethnically diverse cohort of midlife women (n = 2939), to determine if a biomarker of inflammation, high-sensitivity C-reactive protein (hs-CRP), was associated with PMSx. We performed factor analyses with Varimax rotations to determine five groupings of eight symptoms to develop a parsimonious set of outcome variables. We conducted backward stepwise multiple logistic regression models for each grouping, eliminating non-significant (p > 0.05) covariates. RESULTS: Having an hs-CRP level >3 mg/L was significantly positively associated with premenstrual mood symptoms (adjusted odds ratio [aOR] = 1.27, 95% confidence interval [95% CI] 1.02-1.58), abdominal cramps/back pain (aOR = 1.40, 95% CI 1.09-1.80), appetite cravings/weight gain/bloating (aOR = 1.41, 95% CI 1.04-1.89), and breast pain (aOR = 1.26, 95% CI 1.02-1.55). Elevated hs-CRP level was not associated with premenstrual headaches or reporting three or more PMSx. CONCLUSIONS: The significant relationships of specific groups of PMSx with elevated hs-CRP levels have potential clinical implications for treatment and possibly for prevention by advising women about the factors associated with inflammation and the potential for treatment with anti-inflammatory agents.
Authors: Karen A Matthews; Laura L Schott; Joyce Bromberger; Jill Cyranowski; Susan A Everson-Rose; Mary Fran Sowers Journal: Psychosom Med Date: 2007-02-08 Impact factor: 4.312
Authors: Ellen B Gold; Yali Bair; Gladys Block; Gail A Greendale; Siobán D Harlow; Susan Johnson; Howard M Kravitz; Marianne O'Neill Rasor; Amna Siddiqui; Barbara Sternfeld; Jessica Utts; Guili Zhang Journal: J Womens Health (Larchmt) Date: 2007-06 Impact factor: 2.681
Authors: Ellen B Gold; Guibo Xing; Nancy E Avis; Sioban Harlow; Hadine Joffe; Karen Matthews; Jelena M Pavlovic; Rebecca C Thurston; Elaine Waetjen Journal: Menopause Date: 2022-08-01 Impact factor: 3.310
Authors: Lucas da Costa; Italo Ribeiro Lemes; William R Tebar; Crystian B Oliveira; Paulo H Guerra; José Luiz G Soidán; Jorge Mota; Diego G D Christofaro Journal: Braz J Phys Ther Date: 2022-10-13 Impact factor: 4.762
Authors: N Dubey; J F Hoffman; K Schuebel; Q Yuan; P E Martinez; L K Nieman; D R Rubinow; P J Schmidt; D Goldman Journal: Mol Psychiatry Date: 2017-01-03 Impact factor: 15.992